A recent study published in JAMA Network Open confirms that gender-affirming hormone treatment significantly reduces depression among transgender adults, reinforcing the necessity of accessible healthcare for the trans community.
The study followed 3,592 patients from community health centers in Boston and New York over four years. Findings revealed that transgender individuals receiving hormone therapy were 15% less likely to experience moderate-to-severe depression compared to those without access to treatment.
“Trans lives are at risk, and access to life-saving care is essential for well-being and survival,” said Dr. Sari Reisner, the study’s lead author and associate professor at the University of Michigan.
The mental health crisis among transgender individuals is staggering: one in three trans adults experience depression—nearly four times the rate of major depressive episodes in the general U.S. population (8.3%). Experts attribute this disparity to minority stress, systemic discrimination, and limited access to healthcare.
“This study confirms what we’ve known for years—gender-affirming care is critical for both physical and mental well-being,” said Dr. Michelle Forcier of TransHealth. “Denying this access only creates more mental health crises.”
Yet, despite overwhelming scientific evidence, legislative efforts to restrict gender-affirming care continue to rise, jeopardizing trans individuals’ well-being. From bans on trans healthcare to civil rights rollbacks, these policies have profound consequences for transgender people’s mental and physical health.
These findings reinforce the urgent need for inclusive healthcare policies that protect transgender individuals’ right to life-saving medical care, ensuring they can live healthier, more fulfilling lives without unnecessary barriers.
